Blog
RSS FeedPosted by Michael Wonder on 06 Sep 2020
NICE not supportive of encorafenib for metastatic colorectal cancer
4 September 2020 - NICE has responded to the request of the Department of Health and Social Care to produce ...
Posted by Michael Wonder on 02 Sep 2020
NICE terminates yet another assessment of a new cancer medicine
2 September 2020 - This time it is a new medicine for patients with acute myeloid leukaemia. ...
Posted by Michael Wonder on 02 Sep 2020
NICE green light for immunotherapy Bavencio
2 September 2020 - NICE has now published final guidelines endorsing NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) ...
Posted by Michael Wonder on 28 Aug 2020
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
28 August 2020 - MSD’s Keytruda (pembrolizumab) in combination with Pfizer's Inlyta (axitinib) has been turned down by NICE as ...
Posted by Michael Wonder on 20 Aug 2020
New agreement means NICE recommends combination treatment for some lymphoma patients
20 August 2020 - Hundreds of people with a form of blood cancer will benefit from a new treatment following the ...
Posted by Michael Wonder on 17 Aug 2020
Janssen and others have appealed NICE's decision to reject abiraterone acetate for patients with for high risk hormone-sensitive metastatic prostate cancer
17 August 2020 - The appeal panel will convene on 3 September and 4 September to hear oral representations from the ...
Posted by Michael Wonder on 17 Aug 2020
NICE publishes guidance on Astellas' Xospata
17 August 2020 - The National Institute for Health and Care Excellence has now published final guidance backing NHS use ...
Posted by Michael Wonder on 13 Aug 2020
NICE recommends Adcetris for first-line use for patients with a rare form of non-Hodgkin's lymphoma
12 August 2020 - NICE has published its final guidance on the use of brentuximab vedotin in combination with chemotherapy ...
Posted by Michael Wonder on 31 Jul 2020
NICE recommends Bavencio (avelumab) in combination with axitinib for first-line treatment of adult patients with advanced renal cell carcinoma
31 July 2020 - This is the first combination of an immunotherapy with a targeted antiangiogenic therapy to be recommended ...
Posted by Michael Wonder on 30 Jul 2020
NICE rejects NHS funding for Kyowa Kirin's Poteligeo
30 July 2020 - NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis ...
Posted by Michael Wonder on 17 Jul 2020
NICE backing for Astellas' Xospata
17 July 2020 - NICE has recommended use of Astellas' Xospata (gilteritinib) for adults with relapsed or refractory FLT3 mutation-positive ...
Posted by Michael Wonder on 01 Jul 2020
NICE publishes final guidance for Tecentriq for 2 indications
1 July 2020 - NICE has released final guidance on the use of atezolizumab by patients with small cell lung ...
Posted by Michael Wonder on 25 Jun 2020
Cancer patients to benefit from new histology independent treatment
25 June 2020 - Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug ...
Posted by Michael Wonder on 17 Jun 2020
Disagreement on cancer drug decisions in Europe
15 June 2020 - Despite the efforts of the European Union to promote voluntary cooperation among Health Technology Assessment agencies, different ...
Posted by Michael Wonder on 15 Jun 2020
NICE backs Rozlytrek for subset of NSCLC patients
15 June 2020 - NICE has published final draft guidance backing NHS use of Roche's Rozlytrek (entrectinib) as a treatment ...